Approval · Notice of Compliance 11873 · 2010
HYDROMORPH CONTIN: Notice of Compliance 11873
Issued November 17, 2010
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 11873
- Date
- November 17, 2010
- Company
- Purdue PharmaToronto, Ontario, Canada
- Product type
- Prescription Pharmaceutical
- Submission
- Supplement to a New Drug Submission (SNDS), supplement
- Submission class
- Other
- Reason
- The addition of a 4.5 mg and 9 mg strength. Update to the Product Monograph
- Therapeutic class
- Opioid analgesic
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| HYDROMORPH CONTIN | Not yet assigned | — |
| HYDROMORPH CONTIN | 02359502 | Marketed |
| HYDROMORPH CONTIN | 02359510 | Marketed |
Medicinal ingredients
- HYDROMORPHONE HCL 3 MG per CAP
- HYDROMORPHONE HCL 4.5 MG per CAP
- HYDROMORPHONE HCL 6 MG per CAP
- HYDROMORPHONE HCL 9 MG per CAP
- HYDROMORPHONE HCL 10 MG per CAP
- HYDROMORPHONE HCL 12 MG per CAP
- HYDROMORPHONE HCL 18 MG per CAP
- HYDROMORPHONE HCL 20 MG per CAP
- HYDROMORPHONE HCL 24 MG per CAP
- HYDROMORPHONE HCL 30 MG per CAP